Comparative Efficacy of Topical Tacrolimus 0.1% and Clobetasol Propionate 0.05% in the Treatment of Alopecia Areata (AA)

Author:

Sajjad Danyal,Muzaffar Bushra,Siddiqui Muhammad Adeel,Hussain Majid,Aslam Sana,Farid Huma

Abstract

Alopecia areata patients can choose from a variety of therapy methods. Each method has advantages and limitations, and its suitability varies for each patient. The medical usefulness of topical corticosteroids in AA is yet debatable. Objective: To assess the effectiveness of topical tacrolimus 0.1% vs. topical clobetasol propionate 0.05% while treating alopecia areata. Methods: Randomized-controlled trial (Double blind) conducted in Dermatology Department, CMH-Abbottabad, from November 2022 to April 2023. The seventy (70) patients with alopecia areata who attended to OPD of CMH Abbottabad between the ages of 20 and 50 were included. The non-probability consecutive sampling method was used. For up to 3 months, patients in Group A used clobetasol propionate 0.05% twice daily, while patients in Group B used topical tacrolimus 0.1% twice daily. Patients were evaluated at the start of each session, four weeks later, eight weeks later, and twelve weeks later. The SALT score was used to estimate hair loss at presentation and during the 3-month follow-up. The degree of response has been characterized by following hair re-growth as excellent (>75%), marked (51-75%), moderate (26-50%), or mild (25%). A p-value of <0.05 was considered significant.  Results: When the efficacy was compared, 26 (74.3%) patients in group-A (mean age 35.23+7.87 years) shown excellent response, while 14 (40%) patients in group-B (mean age 34.29+7.87 years) with significant p-value was 0.028. Conclusions: Clobetasol propionate 0.05% was more efficacious as a therapy choice for stimulating hair re-growth in patients. 

Publisher

CrossLinks International Publishers

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3